☆ 4.5 Letter

Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

Volume 7, Issue 3, Pages 1055-+

Publisher

ELSEVIER SCIENCE BV

DOI: 10.1016/j.jaip.2018.10.041

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

Publisher

ELSEVIER SCIENCE BV

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

Publisher

ELSEVIER SCIENCE BV

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper